Royalty Pharma and J&J partner to develop autoimmune treatment
J&J(US:JNJ) Reuters·2026-03-30 13:14Royalty Pharma and J&J partner to develop autoimmune treatment | Reuters March 30 (Reuters) - Royalty Pharma (RPRX.O), opens new tabsaid on Monday it has signed a $500 million research and development agreement with Johnson & Johnson (JNJ.N), opens new tabto advance an experimental antibody treatment for autoimmune diseases. Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) ...